Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS)

International Journal of Impotence Research volume 19, pages 76–83 (2007)Cite this article

A Corrigendum to this article was published on 03 May 2007

Abstract

To show that tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction (ED) and efficacy is noninferior to that in Caucasian men. Multiple observations in men with ED in national tadalafil study in the US, a multicenter, open-label study, assessed the efficacy of tadalafil 20 mg taken as needed (maximum one dose/day before sexual activity) for 12 weeks by patients with ED in various populations. This analysis focuses on three groups: Caucasian (Reference group), Black American, and Hispanic men. Primary measurement of efficacy was change from baseline in erectile function (EF) domain of the International Index of Erectile Function (IIEF) and the primary analysis was whether efficacy in Black American and Hispanic groups was noninferior to efficacy in the Caucasian group. Secondary efficacy measures included sexual encounter profile (SEP), IIEF intercourse satisfaction (IS) and overall satisfaction (OS) domains, Global Assessment Question (GAQ), and Psychological and Interpersonal Relationship Scale (PAIRS). Safety was assessed from adverse events (AEs) reported by all enrolled patients. The increase in IIEF EF domain score (⩾9.5) from baseline for each group was statistically significant (P<0.001) and clinically relevant. Efficacy of tadalafil in Black American and Hispanic patients was noninferior to the Caucasian group. IS and OS domains of IIEF had a statistically significant increase from baseline (P<0.001). Change from baseline in positive responses to SEP questions for each group was significant (P<0.001). At least 77% of intercourse attempts were successful over various time intervals up to 36 h postdose. At least 88% of patients in the various groups had a positive response to GAQ1. Improvement from baseline in Sexual Self-Confidence and Spontaneity domains of PAIRS was statistically significant (P<0.001). A low number of AEs and a low AE-related discontinuation rate (2.3%) were reported in all groups. Tadalafil 20 mg was as efficacious in Black American and Hispanic men with ED as in Caucasian patients and was well tolerated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

Abbreviations

CI:

confidence interval

ED:

erectile dysfunction

EF:

erectile function

IIEF:

International Index of Erectile Function

IS:

intercourse satisfaction

MedDRA:

Medical Dictionary for Regulatory Activities

MMAS:

Massachusetts Male Aging Study

MOMENTUS:

Multiple observations in men with ED in national tadalafil study in the US

OS:

overall satisfaction

PAIRS:

Psychological and Interpersonal Relationship Scale

PDE5:

phosphodiesterase type 5

SEP:

sexual encounter profile

TEAE:

treatment-emergent adverse events

References

  1. National Institutes of Health Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83–90.

  2. Feldman HA, Golstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  3. Sowers JR, Ferdinand KC, Bakris GL, Douglas JG . Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med 2002; 112: 24–26, 29–30, 33–34.

    Article  Google Scholar 

  4. Gillum RF . Risk factors for stroke in blacks: a critical review. Am J Epidemiol 1999; 150: 1266–1274.

    Article  CAS  Google Scholar 

  5. Haffner SM, Morales PA, Hazuda HP, Stern MP . Levels of control of hypertension in Mexican-Americans and non-Hispanic whites. Hypertension 1993; 21: 83–88.

    Article  CAS  Google Scholar 

  6. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK . Risk factors for cardiovascular mortality in Mexican-Americans and non-Hispanic whites. San Antonio heart study. Am J Epidemiol 1990; 131: 423–433.

    Article  CAS  Google Scholar 

  7. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332.

    Article  CAS  Google Scholar 

  8. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763.

    CAS  Google Scholar 

  9. Goldstein G, Lue TF, Padma-Nathan H, Rosen R, Steers W, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397.

    Article  CAS  Google Scholar 

  10. Carson CC, Rajfer J, Eardley I, Carrier S, Dennes JS, Walker DJ et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276.

    Article  CAS  Google Scholar 

  11. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S . Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80–86.

    Article  Google Scholar 

  12. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS . Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998; 52: 848–852.

    Article  CAS  Google Scholar 

  13. Kulkarni PM, Meadows ES, Ahuja S, Muram D, Plouffe L . Rationale for a non-inferiority clinical trial design focused on subpopulations. Curr Med Res Opin 2004; 20: 1641–1647.

    Article  CAS  Google Scholar 

  14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  15. Mulhall JP . Deciphering erectile dysfunction drug trials. J Urol 2003; 170: 353–358.

    Article  Google Scholar 

  16. Rosen RC, Swindle R, Lockhart D, Cameron A . Psychological and Interpersonal Relationship Scales (PAIRS): a new tool to measure psychological and relationship impacts of ED treatments. Presented at: 5th Congress of the European Society for Sexual and Impotence Research. December 1–4, 2002; Hamburg, Germany.

  17. Points to consider on switching between superiority and non-inferiority. CPMP web site. Available at: http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf. Accessed 18 July 2005.

  18. Agostino RB, Massaro JM, Sullivan LM . Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003; 22: 169–186.

    Article  Google Scholar 

  19. Points to consider on switching between superiority and non-inferiority. CPMP web site. Available at: http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf. Accessed 18 July 2005.

  20. Jones B, Jarvis P, Lewis JA, Ebbutt AF . Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36–39.

    Article  CAS  Google Scholar 

  21. Young JM, Bennet C, Gilhooly P, Wessells H, Ramos DE . Efficacy and safety of sildenafil citrate (Viagra®) in Black and Hispanic American Men. Urology 2002; 60: 39–48.

    Article  Google Scholar 

  22. Bennett J, Shapiro J, Taylor T . Vardenafil improves erectile function in African-American, Hispanic, and Caucasian men with erectile dysfunction (ED). Poster presented at SMSNA 2003.

  23. Morgentaler A, Barada J, Niederberger C, Garcia CS, Natanegara F, Ahuja S et al. MOMENTUS: multiple observations in men with erectile dysfunction in national tadalafil study in the US [abstract]. ASA 2005 Abstract 33.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Massachusetts General Hospital, Boston, MA, USA

    P Gomery, A Bullock, J McGettigan, R Munarriz, F Natanegara, J Hague, C Kuepfer, S Abuja & D Wong

Authors
  1. P Gomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Bullock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J McGettigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Munarriz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Natanegara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Hague
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Kuepfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Abuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Gomery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomery, P., Bullock, A., McGettigan, J. et al. Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). Int J Impot Res 19, 76–83 (2007). https://doi.org/10.1038/sj.ijir.3901484

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901484

Keywords

This article is cited by

Search

Advanced search

Quick links